|
USA-171114-Mechanical Contractors Company Direktoryo
|
Company News :
- OncoSec Announces $2 Million Registered Direct Offering Priced At-The . . .
OncoSec's clinical pipeline is utilizing TAVO™ as a potential treatment for multiple cancer indications either as a monotherapy or in combination with checkpoint inhibitors; with the latter
- OncoSec Announces Pipeline Prioritization and Workforce . . . - BioSpace
OncoSec Medical Incorporated announced a corporate restructuring intended to prioritize development of its lead clinical candidate TAVO™ a plasmid encoding interleukin 12 delivered by intratumoral electroporation, and extend the Company's cash runway
- OncoSec Medical, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
OncoSec Medical is a biomedical company that specializes in creating innovative cancer treatments Their unique technology, OMS electroporation, involves applying short electric impulses to a tumor to create temporary openings in the cellular membrane, allowing therapeutic agents to enter cancer cells more easily
- OncoSec Medical (ONCSQ) Company Profile Description - Stock Analysis
OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer
- OncoSec Medical Incorporated (ONCS:NASDAQ) - quarterlytics. com
Late-stage immuno-oncology company, OncoSec Medical Incorporated, is honing in on the development and commercialization of intra-tumoral DNA-based therapeutics aimed to boost anti-tumor immune responses for cancer treatment
- OncoSec Cuts Workforce, Prioritizes Pipeline - Yahoo Finance
OncoSec Medical Inc (NASDAQ: ONCS) announced a corporate restructuring intended to prioritize the development of its lead clinical candidate TAVO (TAVO-EP) Oncosec is reducing its staff by
- OncoSec Medical Inc (ONCS) - Product Pipeline Analysis, 2023 Update
OncoSec is conducting pipeline programs for various indications which include metastatic melanoma, triple negative breast cancer and solid tumors The company also identifies and develops novel immune-targeting agents for use with the immunogenicity platform
- OncoSec Medical Incorporated Announces Pipeline Prioritization
OncoSec Medical Incorporated announced a corporate restructuring intended to prioritize development of its lead clinical candidate TAVO (TAVO-EP) a plasmid encoding interleukin 12 (IL-12) delivered by intratumoral electroporation, and extend the Company's cash runway
- OncoSec Medical Incorporated - PMC
OncoSec is a biotechnology company pioneering new technologies that harness the body's immune system to fight cancer OncoSec's core immunotherapy platform, ImmunoPulse™, is designed to deliver DNA-based therapeutics directly into tumors and reverse the immuno-suppressive tumor microenvironment
- OncoSec Medical Inc. - VentureRadar
OncoSec has built a deep and diverse clinical pipeline utilizing TAVO™ as a potential treatment for multiple cancer indications either as a monotherapy or in combination with leading checkpoint inhibitors; with the latter potentially enabling OncoSec to address a great unmet medical need in oncology: anti-PD-1 non-responders
|
|